UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009328 |
|---|---|
| Receipt number | R000010953 |
| Scientific Title | Surveillance study of the frequency of the primary aldosteronism included in the hypertensive patient for an untreated hypertensive patient at the time of the first medical examination: multi-center survey. |
| Date of disclosure of the study information | 2012/11/13 |
| Last modified on | 2013/03/21 14:39:44 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Surveillance study of the frequency of the primary aldosteronism included in the hypertensive patient for an untreated hypertensive patient at the time of the first medical examination: multi-center survey.
Acronym
The survey of primary aldosteronism.
Scientific Title
Surveillance study of the frequency of the primary aldosteronism included in the hypertensive patient for an untreated hypertensive patient at the time of the first medical examination: multi-center survey.
Scientific Title:Acronym
The survey of primary aldosteronism.
Region
| Japan |
Condition
Condition
Primary aldosteronism
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Clarify the frequency of the primary aldosteronism in untreated hypertensive patients.
Basic objectives2
Others
Basic objectives -Others
Contribute to a hypertensive patient's treatment
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Frequency of primary aldosteronism
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
The hypertensive patient who is not treated at the time of the first medical examination.
The patient who has not taken the hypotensive drug one month or more.
Key exclusion criteria
The patient who is taking a hypotensive drug.
Target sample size
5000
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Masahiro Sugawara |
Organization
Japan Physicians Association
Division name
Medical Committee
Zip code
Address
2-5 Kandasurugadai, Chiyoda-ku, Tokyo Pref. 101-0062, Japan
TEL
03-3259-6111
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Toru Setoyama |
Organization
Japan Physicians Association
Division name
Secretariat
Zip code
Address
2-5 Kandasurugadai, Chiyoda-ku, Tokyo Pref. 101-0062, Japan
TEL
03-3259-6111
Homepage URL
http://www.japha.jp
jpa@oregano.ocn.ne.jp
Sponsor or person
Institute
Japan Physicians Association
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 11 | Month | 13 | Day |
Related information
URL releasing protocol
Publication of results
Partially published
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 12 | Month | 12 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 02 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
ARR>200,
PRA;below 1.0ng/ml/hr and PAC above 150pg/ml
Management information
Registered date
| 2012 | Year | 11 | Month | 13 | Day |
Last modified on
| 2013 | Year | 03 | Month | 21 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010953
